Contrave is an investigational medication being evaluated for weight loss and maintenance of weight loss. After rigorous testing for safety, this weight loss combination drug is awaiting FDA approval. If approved, commercial launch of the drug is expected in the second half of 2014.
Contrave was studied in clinical trials enrolling more than 4,500 people. The Central Ohio Nutrition Center was selected to participate in this study. In these clinical trials, 53 percent of study participants taking Contrave and 21 percent of those taking placebo lost five percent or more of their body weight over the 12 month trial duration. Many patients saw improvements in cholesterol levels and blood sugar control. Those who combined Contrave with intensive diet and exercise experienced the most reduction in body weight.
Assuming it is approved by the FDA, CONCI will make Contrave available to patients.